https://www.live-feeds.com/feed/grand-rapids-oncologist-says-experimental-pancreatic-cancer-drug-showing-promise-in-trials-offers-hopeContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/grand-rapids-oncologist-says-experimental-pancreatic-cancer-drug-showing-promise-in-trials-offers-hopehttps://www.live-feeds.com/feed/grand-rapids-oncologist-says-experimental-pancreatic-cancer-drug-showing-promise-in-trials-offers-hope#u20695Wed, 01 Jul 2026 23:56:03 +0000Clinical trials for an experimental pill called Daraxonrasib indicate improved survival rates for patients with advanced pancreatic cancer. The drug targets KRAS master switches to extend life expectancy. Medical professionals in Grand Rapids and Chattanooga report that these results offer new hope for treating the disease.What's confirmed:Daraxonrasib is an experimental drug for pancreatic cancer.The drug targets KRAS pancreatic cancer.Trial results showed a nearly doubled median survival of 13.2 months compared to 6.7 months.The drug is designed as a pill for patients with advanced pancreati